Business Wire

PA-BOOMI

19.7.2022 15:22:11 CEST | Business Wire | Press release

Share
Boomi Wins Awards for Best CEOs for Diversity and Best Company for Career Growth, Ranking Top 50 in the Largest Company Category

Boomi TM , the intelligent connectivity and automation leader, today claims two awards from Comparably , a leading workplace culture and corporate brand reputation platform, in their largest company category along with other 2022 honorees such as Microsoft, Adobe, IBM, Uber, and SADA. Honored with the Best CEOs for Diversity and Best Company for Career Growth awards – based on anonymous employee feedback from its more than 1,700 global employees – Boomi ranks among the top 50 largest companies for its commitments to, and achievements in, diversity and career advancement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719005282/en/

“At Comparably we reward transparency in the workplace,” said Jason Nazar, co-founder and CEO at Comparably. “These awards empower employees to share personal insights about their company’s culture, rewarding and highlighting companies like Boomi, that do great work and set up their employees for success.”

Comparably selected the winners by evaluating over 15 million anonymous employee ratings across 70,000 of the largest companies. Boomi employees ranked their professional development opportunities, such as meaningful career advancement, mentorship, and valuable feedback, as high, which led to Boomi’s recognition among Best Companies for Career Growth. In awarding Best CEOs for Diversity to Boomi, Comparably evaluated ratings of Meredith from Boomi’s employees of color. The 2022 award for Meredith marks his second consecutive year receiving this important designation.

“As a category-leading, high growth, global software as a service (SaaS) company, Boomi strives to create and maintain a world-class employee experience,” said Shawn Maurice, Chief Human Resources Officer at Boomi. “We live by our motto of ‘hiring good humans’ and our unique, core values of Go Beyond, Play for Each Other, Create Awesome Things, Own It, and Build Trust. Boomi’s success ultimately lies in the hands of our team members, and we prioritize creating and nurturing an environment that supports their development and well-being, as well as encouraging them to be bold and find innovative, new solutions to challenges. These awards validate Boomi’s celebrated company culture as we continue to invest in our people.”

As the pioneer and category leader of cloud-native integration platform as a service (iPaaS), Boomi recently surpassed 20,000 customers , setting an industry record for largest customer base among iPaaS vendors. The company boasts a growing user community of over 100,000 members , a worldwide network of more than 800 partners , and one of the largest arrays of global system integrators (GSIs) in the iPaaS space. Boomi’s low-code platform helps organizations across all industries connect data applications, streamline workflows, and deliver more integrated customer experiences.

Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for Enterprise Integration Platform as a Service (EiPaaS) for eight consecutive years .

The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces .

For a list of open positions on the Boomi team, visit the careers page on the Boomi website.

Additional Resources

Gartner Disclaimer:
Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.

About Boomi
Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com .

About Comparably
Comparably is a leading workplace culture and corporate brand reputation platform with over 15 million anonymous employee ratings on 70,000 companies. With the most comprehensive data on large and SMB organizations in nearly 20 different workplace categories – based on gender, ethnicity, age, experience, industry, location, education – it is one of the most used SaaS platforms for employer branding and a trusted third party site for workplace culture and compensation. For more information on Comparably’s studies and annual Best Places to Work Awards, visit Comparably News .

About Comparably Awards
Comparably Awards is an annual series highlighting the best companies and CEOs in 16 different workplace culture categories throughout the year. Since launching in late 2017, the awards have always been based solely on sentiment feedback provided by current employees who anonymously rated their employers on Comparably.com during a 12- month look-back period. Employees can answer structured questions (in yes/no, true/false, 1-10 scale, and multiple choice formats) spanning 16 different workplace topics. Each answer is then given a numerical score and compared to companies of similar size. The final data set of winners are compiled from over 15 million ratings across 70,000 companies.

Link:

ClickThru

Social Media:

https://www.facebook.com/Boomi.Official

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye